Aakaar Medical Technologies Limited — Important, 13-08-2025: Arrangements for strategic, technical, manufacturing, or marketing tie up

Aakaar Medical Technologies has inked three key exclusive distribution deals to expand its portfolio. With Hugel Inc. (Korea), it will exclusively distribute US FDA-approved Letybo, a botulinum toxin, enhancing India's aesthetics market. A partnership with VM Corporation SRLS (Italy) brings advanced exosome-based hair restoration, skin rejuvenation, and body contouring solutions. Lastly, a domestic agreement with Invex Health grants exclusive marketing rights for Tinefcon®, a unique Psoriasis management therapy. These agreements are expected to significantly boost revenue and strengthen Aakaar's position in the medical aesthetics and dermatology sectors.